IP Library Patent Application 14432065
Patent Application
App. No. 14/432,065

CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/432,065
Abstract

Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.

Claims (46)

1 . A switch for activating a chimeric antigen receptor-effector cell (CAR-EC), the switch comprising:

a. a chimeric antigen receptor-interacting domain (CAR-ID) that interacts with a chimeric antigen receptor on the CAR-EC; and

b. a target interacting domain (TID) comprising an unnatural amino acid, wherein the TID interacts with a surface molecule on a target cell.

2 . The switch of claim 1 , wherein the CAR-ID is attached to the TID.

3 . The switch of claim 1 , wherein the CAR-ID is attached to the TID via the unnatural amino acid.

4 . The switch of claim 1 , wherein the CAR-ID is site-specifically attached to the unnatural amino acid of the TID.

5 . The switch of claim 1 , further comprising a linker.

6 . The switch of claim 5 , wherein the linker attaches the CAR-ID to the TID.

7 . The switch of claim 5 , wherein the linker attaches the CAR-ID to the TID via the unnatural amino acid.

8 . The switch of claim 5 , wherein the linker site-specifically attaches the CAR-ID to the unnatural amino acid of the TID.

9 . The switch of claim 5 , wherein the linker comprises an aminooxy group, azide group cyclooctyne group, or a combination thereof at one or more termini.

10 . The switch of claim 1 , wherein the CAR-ID comprises a small molecule.

11 . The switch of claim 10 , wherein the small molecule is a hapten.

12 . The switch of claim 10 , wherein the small molecule is fluorescein isothiocyanate (FITC).

13 . The switch of claim 12 , wherein the TID is conjugated to an isothiocyanate of FITC.

14 . The switch of claim 12 , further comprising a linker that is conjugated to an isothiocyanate of FITC.

15 . The switch of claim 10 , wherein the small molecule is biotin.

16 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of an antibody.

17 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of a single chain variable fragment (scFv).

18 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of an anti-CD19 antibody.

19 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of a single chain variable domain (scFv) of an anti-CD19 antibody.

20 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of an antibody selected from the group consisting of anti-CD20, anti-CD22, anti-CD33, anti-BMSA, anti-CEA, anti-CLL1, anti-CS1, anti-EGFR, and anti-Her2.

21 . The switch of claim 1 , wherein the TID is based on or derived from at least a portion of a single chain variable domain (scFv) of an antibody selected from the group consisting of anti-CD20, anti-CD22, anti-CD33, anti-BMSA, anti-CEA, anti-CLL1, anti-CS1, anti-EGFR, and anti-Her2.

22 . The switch of claim 16 , wherein the unnatural amino acid is inserted in the portion of the antibody from which the TID is based or derived.

23 . The switch of claim 16 , wherein the unnatural amino acid replaces an amino acid of the antibody from which the TID is based or derived.

24 . A composition comprising a plurality of switches for activating a chimeric antigen receptor-effector cell (CAR-EC), wherein a switch of the plurality of switches comprises (a) a chimeric antigen receptor-interacting domain (CAR-ID) that interacts with a chimeric antigen receptor on the CAR-EC; and (b) a target interacting domain (TID) that interacts with a surface molecule on a target cell, wherein at least about 60% of the switches are structurally homologous.

25 . (canceled)

26 . A composition comprising a plurality of switches for activating a chimeric antigen receptor-effector cell (CAR-EC), wherein a switch of the plurality of switches comprises (a) a chimeric antigen receptor-interacting domain (CAR-ID) that interacts with a chimeric antigen receptor on the CAR-EC; and (b) a target interacting domain (TID) comprising a polypeptide, wherein the CAR-ID is attached to the same predetermined site in the TID in at least 60% of the switches.

27 - 33 . (canceled)

34 . The composition of claim 26 , wherein the predetermined site in the TID is an amino acid residue.

35 . The composition of claim 34 , wherein the amino acid residue is an unnatural amino acid.

36 . A switch intermediate for activating a chimeric antigen receptor-effector cell (CAR-EC), the switch intermediate comprising:

a. a chimeric antigen receptor-interacting domain (CAR-ID) comprising a small molecule, wherein the CAR-ID interacts with a chimeric antigen receptor on the CAR-EC; and

b. a linker connected to the CAR-ID, wherein the linker does not comprise a region that interacts with the CAR-EC and the linker does not comprise a region that interacts with a surface molecule on a target cell.

37 .- 40 . (canceled)

41 . The switch intermediate of claim 36 , wherein the CAR-ID comprises fluorescein isothiocyanate (FITC).

42 . A switch intermediate for activating a chimeric antigen receptor-effector cell (CAR-EC), the switch intermediate comprising:

a. a target interacting domain (TID) comprising an unnatural amino acid, wherein the TID interacts with a surface molecule on a target cell; and

b. a linker connected to the TID, wherein the linker does not comprise a region that directly interacts with the CAR-EC and the linker does not comprise a region that directly interacts with the target cell.

43 .- 49 . (canceled)

50 . The switch intermediate of claim 42 , wherein the TID is based on or derived from an antibody or antibody fragment.

51 . The switch intermediate of claim 42 , wherein the TID comprises one or more unnatural amino acids.

52 . A method of producing a switch comprising (a) a chimeric antigen receptor-interacting domain (CAR-ID); and (b) a target interacting domain (TID), the method comprising:

a. coupling a first linker to the TID to produce a first switch intermediate comprising the first linker conjugated to the TID;

b. coupling the first switch intermediate to the CAR-ID, thereby producing the switch.

53 .- 60 . (canceled)

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2015
From: KIM, CHANHYUK; YOUNG, TRAVIS; MA, JENNIFER; KIM, MINSOO; PINKERTON, STEPHANIE A.; SCHULTZ, PETER G.
To: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 035741/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2015
From: CAO, YU; SCHULTZ, PETER G.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 035796/0791 →